Journal of Psychopharmacology
November 16, 2023
Oliver Rumle Hovmand, Emil Deleuran Poulsen, Sidse Arnfred
31 citations
Background: The classical psychedelics psilocybin, peyote, ayahuasca/ N, N-dimethyltryptamine, and lysergic acid diethylamide can temporarily produce altered states of consciousness, characterized by changes in sensory perception, thought, mood, and the sense of self-reality and meaning. It is important to have reliable instruments for quantifying these altered states in trials, due to a...
Pharmacological Reports
October 24, 2023
Agnieszka Wsół
56 citations
Abstract Psychedelics are powerful psychoactive substances that alter perception and mood processes. Their effectiveness in the treatment of psychiatric diseases was known before their prohibition. An increasing number of recent studies, due to the indisputable resurgence of serotonergic hallucinogens, have shown their efficacy in alleviating depression, anxiety, substance abuse therapies, and...
bioRxiv (Cold Spring Harbor Laboratory)
October 9, 2023
Marina D. Luccioni, Jules T. Wyman, Edgard O. Espinoza et al.
2 citations
preprint
Abstract The Sonoran Desert Toad ( Incilius alvarius ) is the only animal known to secrete the psychedelic compound 5-MeO-DMT as a chemical defense, but the source of 5-MeO-DMT in I. alvarius remains unknown. Some amphibians endogenously produce chemical defenses while others acquire them from specialized diets. In this study we analyzed toxin gland secretions and diet profiles from wild I....
IBRO Neuroscience Reports
October 1, 2023
Mariana Pazos, Ignacio Carrera, Giselle Prunell
1 citation
Ayahuasca is a psychedelic beverage originally from the Amazon rainforest used in different shamanic settings for a variety of medicinal, spiritual, and cultural purposes. It is prepared by decoction of the vine Banisteriopsis caapi, source of β-carboline alkaloids, and, Psychotria viridis containing the classic psychedelic N,N-dimethyltryptamine (DMT). As part of the “renaissance of...
JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY
October 1, 2023
Kelan Thomas
In coming years, pharmacists will begin fielding more questions regarding psychedelic medicine, most notably with the imminent FDA approval of 3,4-methylenedioxymethamphetamine (MDMA) for posttraumatic stress disorder (PTSD) expected in 2024 and psilocybin for major depressive disorder (MDD) likely in 2025. Psychedelics are unique medications in many ways, but especially due to the mental...
ACS Medicinal Chemistry Letters
September 14, 2023
Robert B. Kargbo
3 citations
Neurological diseases often involve changes in synaptic connectivity and plasticity. Psychoplastogens, substances that stimulate neuronal growth and enhance neural structures, show promise in mitigating these changes. They activate key biological targets, including AMPA receptors, TrkB, and mTOR. Substances like ketamine, scopolamine, N,N-dimethyltryptamine, and rapastinel have...
American Journal of Psychiatry Residents Journal
September 8, 2023
Lawrence Canale, Dhvanit Raval, Preet Chatha et al.
Psychedelics as therapeutic agents have generated significant attention from clinicians and media sources in recent years. The authors provide an update to the psychiatric trainee on the evidence for psychedelics in the treatment of major depressive disorder and treatment-resistant depression. Many modern clinical trials of the classic, serotonergic psychedelics, such as psilocybin, ayahuasca,...
Fitoterapia
September 1, 2023
Samane Jahanabadi, Shayan Amiri, Mehdi Karkeh-Abadi et al.
14 citations
Natural psychedelic compounds are emerging as potential novel therapeutics in psychiatry. This review will discuss how natural psychedelics exert their neurobiological therapeutic effects, and how different neurotransmission systems mediate the effects of these compounds. Further, current therapeutic strategies for depression, and novel mechanism of action of natural psychedelics in the...
Journal of Applied Toxicology
August 30, 2023
Natália Bernardi Videira, Vijayalekshmi Nair, Valérie Paquet et al.
2 citations
Abstract Serotonergic psychedelics, such as lysergic acid diethylamide (LSD), psilocybin, dimethyltryptamine (DMT), and 5‐methoxy‐ N , N ‐dimethyltryptamine (5‐MeO‐DMT), are currently being investigated for the treatment of psychiatric disorders such as depression and anxiety. Clinical trials with psilocybin and LSD have shown improvement in emotional and psychological scores. Although these...
Journal of Psychoactive Drugs
August 24, 2023
Stanley Wong, An Yi Yu, Nicholas Fabiano et al.
11 citations
There has been a resurgence of interest in the use of psychedelic therapies for several mental and substance use disorders. Psilocybin, a "classic" serotonergic psychedelic, has emerged as one of the primary compounds of interest in clinical research. While research on psilocybin's potential mental health benefits has grown, data on the safety and efficacy of other serotonergic psychedelics...